Context Therapeutics (NASDAQ:CNTX) is focused on developing T-cell engager (TCE) therapies for solid tumors, with an emphasis ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed ...

Christopher J. Schaber, PhD, Chairman, President, and Chief Executive Officer of Soligenix (NASDAQ: SNGX), discusses the ...

Cbio cleanrrom harvest Operator preparing the cell harvester for final product COPENHAGEN, Denmark, March 12, 2026 (GLOBE ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

Gothenburg, March 11, 2023 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells ...

Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

HONG KONG SAR - Media OutReach Newswire - 10 March 2026 - CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Company", Stock Code: 0775) today announced the establishment of ...

News, features, and commentary about cancer-related issues ...

Copenhagen, Denmark Saturday, March 14, 2026, 14:00 Hrs [IST] ...